The tumor microenvironment is a complex, dynamic cellular ecosystem comprising cancer cells, stromal cells, immune infiltrates, extracellular matrix components, and signaling molecules. This milieu profoundly influences tumor biology, modulating proliferation, invasion, and response to therapy. Altundag emphasizes that the neoadjuvant setting, wherein systemic therapy is administered prior to surgical resection, presents a unique opportunity to leverage TME characteristics in real-time. This approach could optimize therapeutic regimens by tailoring drug selection and timing according to TME status, thereby potentially enhancing tumor downstaging and minimizing systemic toxicity.

Central to this integration is a nuanced understanding of immune contexture within the TME. Tumor-infiltrating lymphocytes, macrophages, dendritic cells, and immunosuppressive populations such as regulatory T cells and myeloid-derived suppressor cells contribute distinctly to therapy responsiveness. Altundag points out that quantifying and characterizing these immune cell subsets through advanced multiplex immunohistochemistry and single-cell RNA sequencing can inform neoadjuvant protocols. For instance, tumors with a “hot” immune phenotype, enriched in cytotoxic T cells, may benefit from combinatory checkpoint inhibitors administered preoperatively, in contrast to “cold” tumors that might require strategies aimed at immune priming.

Moreover, the architecture and composition of the extracellular matrix (ECM) emerge as critical modulators of drug delivery and resistance. Denser stroma can hinder the penetration of chemotherapeutic agents and immunotherapies alike. Altundag’s analysis highlights that ECM remodeling enzymes, such as matrix metalloproteinases, are not mere bystanders but active participants dictating the success of neoadjuvant interventions. Targeting these enzymes or utilizing ECM-modifying agents could facilitate deeper drug infiltration and improve cytotoxic efficacy before surgery.

Hypoxia within the TME also plays a nontrivial role in dictating treatment outcomes. Oxygen-deprived tumor zones not only promote genetic instability and aggressive phenotypes but also induce resistance to radiation and certain chemotherapies. Integrating hypoxia markers into pre-treatment assessments permits the customization of neoadjuvant approaches, for example, employing hypoxia-activated prodrugs or enhancing oxygenation through adjunctive therapies. Altundag’s work thoroughly reviews these strategies, underscoring their promise in overcoming hypoxia-driven resistance.

Another pivotal aspect is the metabolic interplay within the TME. Tumor and stromal cells undergo metabolic reprogramming, resulting in altered nutrient consumption and metabolite secretion that can affect immune function and therapeutic sensitivity. For instance, lactate buildup creates an acidic milieu suppressing T-cell activity. Altundag suggests that metabolic profiling could reveal vulnerabilities to be exploited in neoadjuvant settings, such as combining metabolic inhibitors with conventional therapies to bolster immune-mediated tumor eradication.

The integration of liquid biopsy techniques further amplifies the potential of TME-guided neoadjuvant strategies. Detecting circulating tumor DNA (ctDNA), exosomes, and immune cell profiles in peripheral blood offers minimally invasive windows into the evolving tumor ecosystem during treatment. This real-time monitoring could facilitate adaptive therapy modifications, maximizing efficacy while mitigating adverse effects. Altundag’s synthesis of recent clinical trials conveys how dynamic TME biomarkers gleaned from liquid biopsies are reshaping personalized neoadjuvant regimens.

Importantly, the paper delves into the implications for tumor heterogeneity, another formidable challenge in oncology. Spatial and temporal heterogeneity within the TME can lead to mixed therapeutic responses, underscoring the need for multiparametric profiling and multi-regional sampling. Altundag argues that harnessing cutting-edge imaging modalities alongside molecular analyses is paramount in constructing comprehensive TME maps that inform neoadjuvant strategy refinement.

The review also contemplates the synergy between neoadjuvant chemotherapy, radiotherapy, and emerging immunotherapy modalities. The TME not only mediates resistance mechanisms but can also be reshaped by these therapies to foster antitumor immunity or conversely induce immunosuppression and fibrosis. Altundag discusses how strategic sequencing and combination of these treatments, aligned with TME characteristics, could amplify therapeutic benefits while curbing deleterious effects.

On a translational level, the work illuminates the critical role of preclinical models that recapitulate the complexity of the human TME, such as patient-derived xenografts and organoids co-cultured with immune components. Such models are indispensable for testing neoadjuvant regimens designed based on TME insights before clinical implementation. Altundag points to recent successes in this arena, bolstering the argument for a systematic integration of TME-focused preclinical studies in drug development pipelines.

This confluence of biological understanding and clinical innovation also brings to the fore challenges regarding biomarker standardization, reproducibility, and data interpretation across diverse patient populations and tumor types. The article calls for concerted efforts in multidisciplinary collaborations, harmonizing data collection and analysis protocols to translate TME research into practice reliably. Investments in bioinformatics and machine learning further enhance the ability to decode complex TME datasets and generate actionable clinical insights.

Ethical considerations emerge as well, particularly concerning patient stratification and access to potentially transformative neoadjuvant therapies guided by TME profiling. Ensuring equitable healthcare delivery and avoiding overtreatment or undertreatment based on emerging biomarkers remain crucial as these personalized strategies gain traction. Altundag advocates for robust clinical trials with diverse cohorts to validate safety and efficacy before widespread adoption.

Looking ahead, the integration of TME-focused diagnostics and therapeutics into neoadjuvant protocols represents a paradigm shift with potential reverberations across oncology practice. The vision articulated in this comprehensive review underscores a future where tumor biology and microenvironmental context are no longer silent determinants of treatment outcomes but active guides shaping individualized care pathways.

In conclusion, this landmark analysis by K. Altundag galvanizes attention around the intricate crosstalk within the tumor microenvironment and its pivotal role in modulating neoadjuvant treatment response. By weaving together molecular, cellular, and clinical insights, the article lays a robust foundation for a new generation of precision oncology approaches aimed at harnessing the full therapeutic potential of neoadjuvant therapy. As ongoing research continues to unravel TME complexity, integrating these insights promises to elevate patient outcomes and redefine cancer care’s frontline.

Subject of Research: Integrating insights from the tumor microenvironment into neoadjuvant treatment strategies in oncology.

Article Title: Integrating tumor microenvironment insights into neoadjuvant strategies.

Article References:
Altundag, K. Integrating tumor microenvironment insights into neoadjuvant strategies.
Med Oncol 43, 48 (2026). https://doi.org/10.1007/s12032-025-03194-2

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s12032-025-03194-2

Bladder cancer is notorious for its high recurrence rates and resistance to conventional therapies, largely due to the barriers that limit effective drug penetration into tumor tissues. Central to this novel therapeutic strategy is the manipulation of tunneling nanotubes (TNTs)—ultrafine, membranous conduits that facilitate direct intercellular communication and cargo exchange. Until now, the practical exploitation of TNTs for drug delivery has remained elusive, hindered by a lack of control over their formation and activity.

The researchers engineered an electrical triggering mechanism that autonomously senses the tumor microenvironment’s unique electrical properties and, in response, activates the formation and function of TNT networks among cancer cells. This activation enables enhanced transport of chemotherapeutic drugs along these nanotube pathways, effectively creating “highways” that funnel therapeutic agents precisely where they are most needed. This bioelectrical feedback loop represents a paradigm shift in how cellular structures can be harnessed for medical intervention.

The underlying technology leverages the intrinsic bioelectric signals present in cancerous tissues, employing them as natural triggers to initiate the assembly of TNTs. The system’s self-driven nature means it requires no external electrical input, thus simplifying integration into clinical protocols and reducing the risk of off-target effects. Detailed mechanistic studies revealed that localized changes in membrane potential and ionic fluxes encourage cells to extend nanotube projections, which then dynamically interlink the tumor mass.

One of the most compelling aspects of this discovery is the system’s selectivity and scalability. By fine-tuning the electrical parameters responsive to bladder cancer cells, the researchers ensured that healthy tissues remain largely unaffected, limiting collateral damage often observed with systemic chemotherapy. Furthermore, the modularity of the approach suggests potential adaptability across various cancer types characterized by distinct electrical signatures, thereby broadening its clinical relevance.

In vitro experiments demonstrated that administering chemotherapeutic agents in conjunction with the electrical triggering system achieved markedly increased intracellular drug concentrations. This amplification of drug delivery was reflected in enhanced cytotoxicity against bladder cancer cell lines, surpassing the effects of standard treatment regimens. Notably, subsequent in vivo studies in murine models mirrored these results, showing significant tumor regression without escalating systemic toxicity.

The system’s design incorporates biocompatible materials capable of interfacing seamlessly with biological tissues, ensuring minimal immune activation or adverse responses. Researchers utilized microfabricated electrodes embedded within biodegradable scaffolds to monitor and respond to the localized electrical milieu, facilitating precise temporal and spatial control over TNT activation. This marriage of materials science and cellular biophysics exemplifies the interdisciplinary nature of contemporary cancer research.

Perhaps the most striking implication of this technology lies in its potential to overcome multidrug resistance, a major hurdle in effective cancer management. By leveraging TNT networks to shuttle drugs directly into resistant cancer cells, the therapy circumvents typical efflux mechanisms and intracellular sequestration that diminish chemotherapeutic efficacy. This targeted approach could markedly improve patient outcomes and reduce the dosages needed, mitigating side effects.

The study also examined the kinetic dynamics of TNT formation and drug transport, revealing that the electrical triggering not only accelerates the initiation of nanotubes but also enhances their stability and cargo capacity. These properties are crucial for maintaining sustained delivery over therapeutic windows, ensuring consistent drug exposure within tumor microenvironments that are often heterogeneous and difficult to penetrate.

Importantly, the research team addressed potential safety concerns, performing longitudinal analyses to ascertain whether prolonged activation of TNT networks could inadvertently facilitate metastatic spread or intercellular transfer of oncogenic material. Encouragingly, no evidence suggested that TNT activation promoted adverse cellular behaviors, alleviating fears about unintended consequences of this intervention.

The implications for personalized medicine are profound. By integrating real-time bioelectrical monitoring capabilities, treatment regimens could be dynamically adjusted based on individual tumor responses, allowing for bespoke therapies that adapt over the course of disease progression. This would represent a significant leap forward from the static dosing schedules currently prevalent in oncology.

This discovery also sparks new avenues for research into the role of bioelectricity in cancer biology. The ability to manipulate electrical signaling pathways to modulate cell behavior not only opens therapeutic possibilities but may also deepen scientific understanding of tumorigenesis and microenvironmental interactions. Such insights could inform future strategies for early detection and intervention.

While challenges remain in translating this innovative system from bench to bedside—including scaling manufacturing processes, ensuring regulatory compliance, and conducting large-scale clinical trials—the foundational science offers a promising path forward. Collaborative efforts between bioengineers, oncologists, and materials scientists will be vital to harnessing the full potential of tunneling nanotube activation in clinical oncology.

In conclusion, the introduction of a self-driven electrical triggering system to activate TNT highways represents a transformative leap in bladder cancer treatment. By capitalizing on the tumor’s intrinsic bioelectric landscape to promote efficient drug transport, this method promises to enhance therapeutic efficacy while reducing systemic toxicity. As the technology moves closer to clinical application, it heralds a future where cancer therapy is not only more effective but also more intelligent, adaptive, and targeted.

Subject of Research: Bladder cancer therapy and targeted drug delivery mechanisms.

Article Title: Self-driven electrical triggering system activates tunneling nanotube highways to enhance drug delivery in bladder cancer therapy.

Article References:
Liu, Z., Joshi, R., Zhou, Z. et al. Self-driven electrical triggering system activates tunneling nanotube highways to enhance drug delivery in bladder cancer therapy. Nat Commun 16, 10093 (2025). https://doi.org/10.1038/s41467-025-65017-2

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-025-65017-2

Central to the ACTM-838 approach is its capacity to systemically administer a live attenuated bacterial vector optimized for tumor localization. Upon intravenous delivery, this modified Salmonella Typhimurium strain preferentially accumulates within solid tumors, exploiting its innate ability to target phagocytic cells residing in the TME. This selective tropism facilitates concentrated delivery of therapeutic proteins while minimizing exposure to healthy tissues, thereby substantially mitigating systemic toxicity—a significant concern in earlier bacterial therapies.

The payload delivered by ACTM-838 comprises a sophisticated fusion of immune agonists: the interleukin-15/interleukin-15 receptor alpha complex (IL-15/IL-15Rα) alongside a modified Stimulator of Interferon Genes (STING) agonist. IL-15/IL-15Rα plays a pivotal role in stimulating the proliferation and activation of cytotoxic lymphocytes, fostering robust adaptive immune responses. Meanwhile, the STING pathway acts as a critical sensor within innate immunity, activating type I interferon responses essential for initiating potent anti-tumor immunity. The architectural design of ACTM-838 ensures co-delivery of these complementary factors to reprogram the immunosuppressive TME towards an immunogenic milieu conducive to sustained tumor eradication.

Preclinical investigations detailed in the study demonstrate ACTM-838’s remarkable ability to trigger tumor regression across multiple murine models, including notoriously treatment-resistant variants. This bacterially-mediated therapy not only facilitated significant tumor shrinkage but also conferred durable protection, as evidenced by rechallenge experiments where cured mice resisted tumor recurrence. Such findings suggest the establishment of durable immune memory, a holy grail of cancer immunotherapy aimed at preventing relapse.

Moreover, ACTM-838’s synergy with immune checkpoint blockade therapies such as anti-PD1 monoclonal antibodies underscores its potential clinical utility. Combination treatment regimens exhibited enhanced efficacy beyond monotherapies, reshaping tumor immune landscapes to favor effector T-cell infiltration and reducing immunosuppressive regulatory T-cells and exhausted phenotypes. This dual modality exemplifies the promise of integrating bacterial vectors with existing immunotherapeutic agents to surmount current treatment ceiling effects.

On a mechanistic level, single-cell RNA sequencing analyses revealed novel myeloid subsets that emerge within the TME following ACTM-838 administration. These subsets include proliferative macrophages and metabolically reprogrammed neutrophil populations characterized by distinct transcriptional signatures. Such cellular dynamics underscore the complex innate immune orchestration initiated by this therapy, which collectively drives adaptive response amplification and tumor immune sensitization.

Importantly, the study addresses safety concerns by demonstrating that ACTM-838 markedly reduces inflammatory toxicity compared to its parental bacterial strain. Genetic attenuation strategies curtailed pathogenicity without compromising delivery efficacy, thereby achieving a favorable therapeutic index critical for translational potential. This balance between safety and potency positions ACTM-838 as a viable candidate for progression into clinical trials.

The implications of this research stretch beyond the immediate therapeutic benefits, offering a paradigm shift in delivering multiplexed gene-based immune modulators to the tumor site. By harnessing live bacterial platforms engineered for specific payload delivery, researchers open avenues for versatile, adaptable cancer treatments tailored to diverse tumor types and resistant phenotypes, a significant leap from conventional systemic immunotherapies.

ACTM-838 is currently undergoing Phase I clinical trials, marking a significant milestone in translational oncology research. These trials will probe tolerability, biodistribution, and early efficacy signals in human subjects, setting the stage for potential regulatory approvals and widespread clinical application. Success in these early-phase trials could catalyze a wave of bacterial-based immunotherapies entering the oncological arsenal.

The novelty of ACTM-838 underscores the broader trend of synthetic biology and genetic engineering converging to transform therapeutics. This live bacterial vector harnesses cutting-edge genetic manipulation to introduce complex immunomodulatory payloads that are otherwise challenging to deliver systemically due to bioavailability and toxicity constraints. Such innovations align with the global pursuit of precision oncology.

As the field moves forward, integration of live bacterial therapies with personalized medicine frameworks offers enticing prospects. Tailoring payload combinations and dosing regimens based on individual tumor immunoprofiles could maximize therapeutic responsiveness while minimizing adverse events—objectives at the forefront of next-generation cancer treatment paradigms.

In summary, ACTM-838 exemplifies a sophisticated and promising approach that merges microbial engineering with immuno-oncology to tackle the formidable challenge posed by solid tumors’ immune evasion. Its capacity to safely deliver IL-15/IL-15Rα and STING agonists within the tumor microenvironment, stimulate both innate and adaptive immunity, and generate durable anti-tumor effects positions it as a beacon of hope for patients unresponsive to existing therapies. This pioneering research paves the way for an exciting era where live bacterial therapies redefine the boundaries of cancer treatment.

Subject of Research: Not applicable

Article Title: ACTM-838, a novel systemically delivered bacterial immunotherapy that enriches in solid tumors and delivers IL-15/IL-15Rα and STING payloads to engage innate and adaptive immunity in the TME and enable a durable anti-tumor immune response

News Publication Date: 6-Oct-2025

Web References:

• Article DOI: 10.18632/oncotarget.28769
• Actym Therapeutics: https://www.actymthera.com/
• Oncotarget: https://www.oncotarget.com/archive/v16/

Image Credits: Copyright: © 2025 Cron et al. This is an open access article under CC BY 4.0 license.

Keywords: cancer, oncology, tumor microenvironment, bacterial vector, myeloid cells, STING, IL-15

The foundation of any successful ADC lies in its target antigen—proteins expressed on the surface of cancer cells that guide the conjugated antibody directly to malignant tissues. Ideally, these targets should be abundantly expressed on tumor cells and absent or minimally present on healthy tissues to avoid off-target toxicity. However, the identification of such ideal antigens remains a formidable hurdle. Most candidate targets display heterogeneous expression patterns within tumors and, crucially, are also present in normal tissues at varying levels, potentially triggering life-threatening side effects.

The development and clinical deployment of HER2-targeted ADCs illustrate this conundrum vividly. Trastuzumab deruxtecan, a notable third-generation ADC targeting HER2-positive cancers, has demonstrated remarkable efficacy in breast and gastric cancers. Yet, the underlying expression of HER2 in cardiac and pulmonary tissues poses a significant risk, with patients occasionally experiencing severe cardiotoxicity and respiratory diseases. This duality underscores how even effective ADCs can be compromised by the biology of their selected antigens, necessitating rigorous antigen distribution profiling beyond tumor sites.

Other targets, such as Trop2 and the epidermal growth factor receptor (EGFR), similarly betray the challenge of balancing efficacy and safety. Trop2, despite its therapeutic potential, has broad expression across normal epithelial tissues, resulting in widespread toxicity when targeted by ADCs. Likewise, EGFR-targeting conjugates, while potent, are prone to induce severe infusion reactions and ocular toxicities. These adverse outcomes reflect a narrow therapeutic window and highlight the urgent need for precision in antigen selection and ADC design.

Among emerging ADC targets, Claudin-18 (CLDN18) emerges as a beacon of promise. Unlike HER2, Trop2, or EGFR, Claudin-18 boasts restricted expression in normal tissues but is highly prevalent in several tumor types, particularly gastric cancers. Early-phase clinical trials utilizing CLDN18-directed ADCs report minimal adverse effects, positioning it as a safer alternative for targeted therapy. The success of Claudin-18-based ADCs may pave the way toward a new paradigm of high-efficacy, low-toxicity treatments, sparking renewed interest in exploring tissue-restricted antigens.

Critical to overcoming the inherent complexities of target selection is the integration of advanced technologies. Single-cell sequencing allows researchers to dissect intratumoral heterogeneity at an unprecedented resolution, revealing nuanced antigen expression patterns that could inform more selective targeting strategies. Simultaneously, artificial intelligence algorithms are being leveraged to predict antigen distribution and toxicity profiles, streamlining the identification of optimal target candidates and minimizing the risk of off-target effects.

Moreover, innovations in antibody engineering and linker chemistry remain indispensable for augmenting ADC efficacy and safety. The design of more stable linkers that release cytotoxic payloads exclusively within tumor cells, coupled with antibodies engineered for enhanced specificity, collectively shift the therapeutic window in favor of patient benefit. Such technological refinements ensure that ADCs can deliver their lethal cargo precisely where needed, sparing healthy tissues from collateral damage.

The pathway to broader ADC applicability also hinges on overcoming resistance mechanisms that tumors frequently develop. Cancer cells can alter antigen expression or enhance drug efflux systems, leading to therapy evasion. Strategies combining ADCs with immunotherapies or other chemotherapeutic agents hold immense promise in circumventing resistance, leveraging synergistic effects to enhance tumor cell killing and sustain clinical responses.

Despite these advancements, challenges remain formidable. The dynamic microenvironment of tumors, including hypoxia and immune modulation, influences antigen presentation and drug delivery efficacy. Additionally, interpatient variability adds layers of complexity to ADC administration, necessitating personalized treatment approaches and biomarkers to predict and monitor responses effectively.

The review poignantly characterizes the “Icarian flight” of ADCs—a metaphor illustrating the ambition and peril of these therapies as they soar toward transformative cancer treatment but risk downfall without cautious calibration. Our collective endeavor to harness ADCs safely and effectively demands multidisciplinary collaboration, spanning molecular biology, clinical oncology, bioinformatics, pharmacology, and beyond.

Looking forward, the fusion of cutting-edge science with clinical insight offers a compelling roadmap. Continued exploration of novel antigens such as Claudin-18, coupled with adaptive trial designs and real-time biomarker assessments, will refine therapeutic indices. Furthermore, deepening our understanding of tumor biology through spatial transcriptomics and advanced imaging will enable more precise ADC deployment.

In conclusion, antibody-drug conjugates embody a powerful but intricate weapon in the cancer therapy arsenal. The delicate interplay of antigen selection, payload potency, antibody specificity, and patient heterogeneity dictates their success or failure. Optimizing these variables through technological innovation and biological insight holds the key to expanding the impact of ADCs beyond current limitations, ultimately delivering safer and more effective treatments to patients worldwide.

Subject of Research: Not applicable
Article Title: The Icarian flight of antibody-drug conjugates: target selection amidst complexity and tackling adverse impacts
News Publication Date: 15-Jan-2025
Web References: 10.1093/procel/pwaf002
Image Credits: Han Liu, Hongye Zeng, Xiaojing Qin, Wenjing Ning, Lin Xu, Shiting Yang, Xue Liu, Wenxin Luo, Ningshao Xia